FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer

被引:41
作者
Duong, Cuong P.
Hicks, Rodney J.
Weih, LeAnn
Drummond, Elizabeth
Leong, Trevor
Michael, Michael
Thomas, Robert J. S.
机构
[1] Peter MacCallum Canc Ctr, Ctr Mol Imaging, Melbourne, Vic 8006, Australia
[2] Peter MacCallum Canc Ctr, Div Surg Oncol, Melbourne, Vic 8006, Australia
[3] Peter MacCallum Canc Ctr, Dept Stat, Melbourne, Vic 8006, Australia
基金
英国医学研究理事会;
关键词
FDG-PET; oesophageal cancer; tumour response; chemoradiotherapy; impact;
D O I
10.1007/s00259-005-0040-z
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: The purpose of this study was to evaluate the impact of FDG-PET following chemoradiotherapy (CRT) on treatment planning and survival in patients with oesophageal cancer (OC). Methods: Fifty-three consecutive OC patients had a post-treatment PET scan to evaluate tumour response to CRT prior to possible surgery. Baseline pre-CRT PET was performed in 33 patients. Prospectively recorded post-CRT management plans were compared with post-PET treatment. High impact was defined as a change in treatment intent or modality. Survival was analysed using the Kaplan-Meier product limit method and Cox proportional hazards regression model. Results: After completion of CRT, 23/53 patients (43%) achieved complete metabolic response (CMR), as compared with only four (8%) with complete response on computed tomography. High PET impact was observed in 19 patients (36%). CMR was strongly predictive of survival (p < 0.008) on multivariate analysis. CMR patients in whom resection was not performed had comparable survival to those (CMR and non-CMR) who underwent resection. Conclusion: The use of post-treatment FDG-PET for assessment of tumour response after CRT changed the clinical management of more than one-third of OC patients. CMR status as assessed by PET powerfully stratified prognosis. Even in the absence of a baseline study, normalisation of uptake at all sites of known tumoral involvement carries a good medium-term prognosis.
引用
收藏
页码:770 / 778
页数:9
相关论文
共 42 条
[1]  
Bar-Shalom R, 2003, J NUCL MED, V44, P1200
[2]  
Beseth BD, 2000, AM SURGEON, V66, P827
[3]   Improvement in staging of esophageal cancer with the addition of positron emission tomography [J].
Block, MI ;
Patterson, GA ;
Sundaresan, RS ;
Bailey, MS ;
Flanagan, FL ;
Dehdashti, F ;
Siegel, BA ;
Cooper, JD .
ANNALS OF THORACIC SURGERY, 1997, 64 (03) :770-776
[4]  
Blot WJ, 1999, SEMIN ONCOL, V26, P2
[5]   Impact of positron emission tomography on the management of patients with small-cell lung cancer - Preliminary experience [J].
Blum, R ;
MacManus, MP ;
Rischin, D ;
Michael, M ;
Ball, D ;
Hicks, RJ .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (02) :164-171
[6]   Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma [J].
Blum, RH ;
Seymour, JF ;
Wirth, A ;
MacManus, M ;
Hicks, RJ .
CLINICAL LYMPHOMA, 2003, 4 (01) :43-49
[7]   Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapy [J].
Brown, WA ;
Thomas, J ;
Gotley, D ;
Burmeister, BH ;
Lim, KH ;
Martin, I ;
Walpole, ET ;
Thomson, DB ;
Harvey, JA ;
Smithers, BM .
BRITISH JOURNAL OF SURGERY, 2004, 91 (02) :199-204
[8]  
Brücher BLDM, 2001, ANN SURG, V233, P300
[9]  
Cohade C, 2003, J NUCL MED, V44, P1797
[10]  
Couper GW, 1998, BRIT J SURG, V85, P1403